nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Dactinomycin—testicular cancer	0.0799	0.119	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—testicular cancer	0.0644	0.0962	CbGbCtD
Dabrafenib—ABCG2—Carboplatin—testicular cancer	0.0537	0.0803	CbGbCtD
Dabrafenib—CYP2C8—Ifosfamide—testicular cancer	0.0503	0.0751	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—testicular cancer	0.0459	0.0686	CbGbCtD
Dabrafenib—ABCG2—Etoposide—testicular cancer	0.0451	0.0674	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—testicular cancer	0.0375	0.056	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—testicular cancer	0.0346	0.0517	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—testicular cancer	0.0308	0.046	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—testicular cancer	0.0298	0.0445	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—testicular cancer	0.0288	0.0431	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—testicular cancer	0.0241	0.036	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—testicular cancer	0.024	0.0359	CbGbCtD
Dabrafenib—CYP3A4—Ifosfamide—testicular cancer	0.0204	0.0305	CbGbCtD
Dabrafenib—ABCB1—Vinblastine—testicular cancer	0.018	0.027	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—testicular cancer	0.0165	0.0247	CbGbCtD
Dabrafenib—ABCB1—Etoposide—testicular cancer	0.0163	0.0243	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—testicular cancer	0.0111	0.0166	CbGbCtD
Dabrafenib—CYP3A4—Vinblastine—testicular cancer	0.0108	0.0162	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—testicular cancer	0.0107	0.0161	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—testicular cancer	0.00974	0.0146	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—testicular cancer	0.00664	0.00993	CbGbCtD
Dabrafenib—NEK11—female gonad—testicular cancer	0.00628	0.107	CbGeAlD
Dabrafenib—NEK11—testis—testicular cancer	0.00557	0.0949	CbGeAlD
Dabrafenib—NEK11—lymph node—testicular cancer	0.00404	0.0688	CbGeAlD
Dabrafenib—LIMK1—testis—testicular cancer	0.00399	0.0679	CbGeAlD
Dabrafenib—RAF1—embryo—testicular cancer	0.00335	0.0572	CbGeAlD
Dabrafenib—RAF1—seminal vesicle—testicular cancer	0.00315	0.0537	CbGeAlD
Dabrafenib—SIK1—LKB1 signaling events—STK11—testicular cancer	0.00308	0.0796	CbGpPWpGaD
Dabrafenib—LIMK1—lymph node—testicular cancer	0.00289	0.0492	CbGeAlD
Dabrafenib—SIK1—gonad—testicular cancer	0.00286	0.0487	CbGeAlD
Dabrafenib—BRAF—female gonad—testicular cancer	0.00278	0.0473	CbGeAlD
Dabrafenib—BRAF—testis—testicular cancer	0.00246	0.042	CbGeAlD
Dabrafenib—SIK1—female gonad—testicular cancer	0.00232	0.0396	CbGeAlD
Dabrafenib—RAF1—gonad—testicular cancer	0.00228	0.0388	CbGeAlD
Dabrafenib—SIK1—testis—testicular cancer	0.00206	0.0351	CbGeAlD
Dabrafenib—RAF1—female gonad—testicular cancer	0.00185	0.0315	CbGeAlD
Dabrafenib—BRAF—lymph node—testicular cancer	0.00179	0.0304	CbGeAlD
Dabrafenib—RAF1—testis—testicular cancer	0.00164	0.028	CbGeAlD
Dabrafenib—SIK1—lymph node—testicular cancer	0.00149	0.0255	CbGeAlD
Dabrafenib—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00147	0.038	CbGpPWpGaD
Dabrafenib—ABCG2—seminal vesicle—testicular cancer	0.0013	0.0222	CbGeAlD
Dabrafenib—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00123	0.0317	CbGpPWpGaD
Dabrafenib—RAF1—lymph node—testicular cancer	0.00119	0.0203	CbGeAlD
Dabrafenib—LIMK1—Developmental Biology—PRDM14—testicular cancer	0.00114	0.0295	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000782	0.0202	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—FGFR3—testicular cancer	0.000774	0.02	CbGpPWpGaD
Dabrafenib—ABCG2—female gonad—testicular cancer	0.000765	0.013	CbGeAlD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000755	0.0195	CbGpPWpGaD
Dabrafenib—CYP2C8—testis—testicular cancer	0.000698	0.0119	CbGeAlD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.000693	0.0179	CbGpPWpGaD
Dabrafenib—ABCB1—embryo—testicular cancer	0.000684	0.0117	CbGeAlD
Dabrafenib—ABCG2—testis—testicular cancer	0.000679	0.0116	CbGeAlD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000668	0.0173	CbGpPWpGaD
Dabrafenib—RAF1—BCR signaling pathway—BCL10—testicular cancer	0.000645	0.0167	CbGpPWpGaD
Dabrafenib—ABCB1—seminal vesicle—testicular cancer	0.000643	0.011	CbGeAlD
Dabrafenib—BRAF—Negative regulation of FGFR signaling—FGFR3—testicular cancer	0.000631	0.0163	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000558	0.0144	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—MMP2—testicular cancer	0.000518	0.0134	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—BCL10—testicular cancer	0.000509	0.0132	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000507	0.0131	CbGpPWpGaD
Dabrafenib—ABCG2—lymph node—testicular cancer	0.000492	0.00839	CbGeAlD
Dabrafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.000484	0.0125	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00048	0.0124	CbGpPWpGaD
Dabrafenib—ABCB1—gonad—testicular cancer	0.000464	0.00791	CbGeAlD
Dabrafenib—LIMK1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000441	0.0114	CbGpPWpGaD
Dabrafenib—RAF1—Kit receptor signaling pathway—KITLG—testicular cancer	0.000431	0.0111	CbGpPWpGaD
Dabrafenib—RAF1—FRS2-mediated cascade—FGFR3—testicular cancer	0.000405	0.0105	CbGpPWpGaD
Dabrafenib—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000396	0.0102	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PRDM14—testicular cancer	0.000395	0.0102	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000384	0.00991	CbGpPWpGaD
Dabrafenib—ABCB1—female gonad—testicular cancer	0.000377	0.00643	CbGeAlD
Dabrafenib—RAF1—IRS-mediated signalling—STK11—testicular cancer	0.000347	0.00897	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000343	0.00886	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00034	0.00877	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events—STK11—testicular cancer	0.000338	0.00873	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.000335	0.00865	CbGpPWpGaD
Dabrafenib—ABCB1—testis—testicular cancer	0.000335	0.0057	CbGeAlD
Dabrafenib—LIMK1—Innate Immune System—BCL10—testicular cancer	0.000333	0.0086	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.00033	0.00853	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—STK11—testicular cancer	0.000326	0.00842	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—STK11—testicular cancer	0.000326	0.00842	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000317	0.00819	CbGpPWpGaD
Dabrafenib—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000297	0.00768	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000296	0.00766	CbGpPWpGaD
Dabrafenib—RAF1—Kit receptor signaling pathway—KIT—testicular cancer	0.000294	0.00759	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000283	0.00732	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—KITLG—testicular cancer	0.000277	0.00716	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000274	0.00707	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—STK11—testicular cancer	0.000271	0.007	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—KITLG—testicular cancer	0.000258	0.00667	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000258	0.00666	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00025	0.00646	CbGpPWpGaD
Dabrafenib—Abdominal pain upper—Epirubicin—testicular cancer	0.000248	0.00106	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—testicular cancer	0.000247	0.00106	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000246	0.00105	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000246	0.00105	CcSEcCtD
Dabrafenib—Pancreatitis—Methotrexate—testicular cancer	0.000246	0.00105	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000244	0.00105	CcSEcCtD
Dabrafenib—ABCB1—lymph node—testicular cancer	0.000243	0.00413	CbGeAlD
Dabrafenib—Hypotension—Cisplatin—testicular cancer	0.000243	0.00104	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—testicular cancer	0.000243	0.00104	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—testicular cancer	0.000242	0.00104	CcSEcCtD
Dabrafenib—Abdominal discomfort—Methotrexate—testicular cancer	0.00024	0.00103	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000239	0.00102	CcSEcCtD
Dabrafenib—RAF1—IRS-mediated signalling—FGFR3—testicular cancer	0.000239	0.00617	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000239	0.00617	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—MMP2—testicular cancer	0.000238	0.00615	CbGpPWpGaD
Dabrafenib—Body temperature increased—Ifosfamide—testicular cancer	0.000238	0.00102	CcSEcCtD
Dabrafenib—Abdominal pain—Ifosfamide—testicular cancer	0.000238	0.00102	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000236	0.00101	CcSEcCtD
Dabrafenib—Infection—Etoposide—testicular cancer	0.000236	0.00101	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—testicular cancer	0.000236	0.00101	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—testicular cancer	0.000235	0.00101	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—testicular cancer	0.000234	0.001	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—testicular cancer	0.000233	0.000999	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—testicular cancer	0.000233	0.000997	CcSEcCtD
Dabrafenib—RAF1—IRS-related events—FGFR3—testicular cancer	0.000232	0.006	CbGpPWpGaD
Dabrafenib—Skin disorder—Etoposide—testicular cancer	0.000231	0.000989	CcSEcCtD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.00023	0.00595	CbGpPWpGaD
Dabrafenib—Dry skin—Doxorubicin—testicular cancer	0.00023	0.000985	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—testicular cancer	0.00023	0.000984	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—testicular cancer	0.00023	0.000984	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—testicular cancer	0.000229	0.000982	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000229	0.00591	CbGpPWpGaD
Dabrafenib—Hypokalaemia—Doxorubicin—testicular cancer	0.000228	0.000978	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000226	0.000968	CcSEcCtD
Dabrafenib—Decreased appetite—Cisplatin—testicular cancer	0.000226	0.000966	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—testicular cancer	0.000225	0.000963	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—testicular cancer	0.000224	0.000961	CcSEcCtD
Dabrafenib—RAF1—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000224	0.00579	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—FGFR3—testicular cancer	0.000224	0.00579	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000224	0.00096	CcSEcCtD
Dabrafenib—Vomiting—Bleomycin—testicular cancer	0.000224	0.000959	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—testicular cancer	0.000223	0.000956	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—testicular cancer	0.000223	0.000956	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—testicular cancer	0.000222	0.000952	CcSEcCtD
Dabrafenib—Rash—Bleomycin—testicular cancer	0.000222	0.000951	CcSEcCtD
Dabrafenib—Dermatitis—Bleomycin—testicular cancer	0.000222	0.00095	CcSEcCtD
Dabrafenib—Hypersensitivity—Ifosfamide—testicular cancer	0.000222	0.00095	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000221	0.000948	CcSEcCtD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.00022	0.00569	CbGpPWpGaD
Dabrafenib—Renal failure—Methotrexate—testicular cancer	0.00022	0.00094	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—testicular cancer	0.000219	0.000939	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—testicular cancer	0.000218	0.000932	CcSEcCtD
Dabrafenib—Asthenia—Ifosfamide—testicular cancer	0.000216	0.000925	CcSEcCtD
Dabrafenib—RAF1—Signaling by SCF-KIT—KITLG—testicular cancer	0.000214	0.00554	CbGpPWpGaD
Dabrafenib—Pruritus—Ifosfamide—testicular cancer	0.000213	0.000912	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—testicular cancer	0.000213	0.000912	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—testicular cancer	0.000213	0.000911	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—testicular cancer	0.000211	0.000906	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—testicular cancer	0.000211	0.000902	CcSEcCtD
Dabrafenib—Nausea—Bleomycin—testicular cancer	0.000209	0.000896	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—testicular cancer	0.000209	0.000895	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—testicular cancer	0.000209	0.000895	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—testicular cancer	0.000209	0.000895	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—testicular cancer	0.000207	0.000887	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—testicular cancer	0.000207	0.000885	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR—FGFR3—testicular cancer	0.000206	0.00533	CbGpPWpGaD
Dabrafenib—Diarrhoea—Ifosfamide—testicular cancer	0.000206	0.000882	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—testicular cancer	0.000205	0.00088	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000205	0.000879	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000205	0.0053	CbGpPWpGaD
Dabrafenib—Body temperature increased—Cisplatin—testicular cancer	0.000205	0.000879	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—testicular cancer	0.000205	0.000878	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—testicular cancer	0.000204	0.000872	CcSEcCtD
Dabrafenib—Constipation—Etoposide—testicular cancer	0.000203	0.000871	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—testicular cancer	0.000203	0.00087	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—testicular cancer	0.000203	0.000869	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—KITLG—testicular cancer	0.000202	0.00522	CbGpPWpGaD
Dabrafenib—Haemoglobin—Methotrexate—testicular cancer	0.000201	0.000863	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—KITLG—testicular cancer	0.000201	0.00519	CbGpPWpGaD
Dabrafenib—Haemorrhage—Methotrexate—testicular cancer	0.0002	0.000859	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—testicular cancer	0.000199	0.000853	CcSEcCtD
Dabrafenib—Dizziness—Ifosfamide—testicular cancer	0.000199	0.000853	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—testicular cancer	0.000198	0.000848	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—testicular cancer	0.000197	0.000844	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—testicular cancer	0.000197	0.000842	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—testicular cancer	0.000196	0.000838	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—testicular cancer	0.000195	0.000836	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—testicular cancer	0.000194	0.000833	CcSEcCtD
Dabrafenib—LIMK1—Immune System—BCL10—testicular cancer	0.000194	0.00501	CbGpPWpGaD
Dabrafenib—Infestation—Doxorubicin—testicular cancer	0.000193	0.000828	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—testicular cancer	0.000193	0.000828	CcSEcCtD
Dabrafenib—RAF1—Downstream signal transduction—KITLG—testicular cancer	0.000193	0.00498	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—MMP2—testicular cancer	0.000193	0.00498	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000192	0.00496	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—KITLG—testicular cancer	0.000192	0.00496	CbGpPWpGaD
Dabrafenib—Vomiting—Ifosfamide—testicular cancer	0.000191	0.00082	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—testicular cancer	0.000191	0.000819	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB2—KITLG—testicular cancer	0.000191	0.00493	CbGpPWpGaD
Dabrafenib—Renal failure—Doxorubicin—testicular cancer	0.00019	0.000814	CcSEcCtD
Dabrafenib—RAF1—DAP12 signaling—KITLG—testicular cancer	0.00019	0.00491	CbGpPWpGaD
Dabrafenib—Rash—Ifosfamide—testicular cancer	0.00019	0.000813	CcSEcCtD
Dabrafenib—Dermatitis—Ifosfamide—testicular cancer	0.00019	0.000812	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR—KIT—testicular cancer	0.000189	0.00489	CbGpPWpGaD
Dabrafenib—Haemoglobin—Epirubicin—testicular cancer	0.000189	0.000808	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—testicular cancer	0.000188	0.000807	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—testicular cancer	0.000188	0.000805	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—testicular cancer	0.000188	0.000805	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—testicular cancer	0.000188	0.000805	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—testicular cancer	0.000188	0.000803	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—testicular cancer	0.000187	0.000802	CcSEcCtD
Dabrafenib—RAF1—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000186	0.00481	CbGpPWpGaD
Dabrafenib—Asthenia—Cisplatin—testicular cancer	0.000186	0.000798	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—testicular cancer	0.000185	0.000793	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—testicular cancer	0.000185	0.000792	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—testicular cancer	0.000184	0.00079	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—testicular cancer	0.000184	0.00079	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—testicular cancer	0.000184	0.000788	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—testicular cancer	0.000182	0.000781	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—testicular cancer	0.000182	0.000779	CcSEcCtD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000182	0.0047	CbGpPWpGaD
Dabrafenib—Immune system disorder—Methotrexate—testicular cancer	0.000181	0.000776	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—testicular cancer	0.000181	0.000774	CcSEcCtD
Dabrafenib—Chills—Methotrexate—testicular cancer	0.00018	0.00077	CcSEcCtD
Dabrafenib—Nausea—Ifosfamide—testicular cancer	0.000179	0.000766	CcSEcCtD
Dabrafenib—RAF1—DAP12 interactions—KITLG—testicular cancer	0.000179	0.00462	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000179	0.00462	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KITLG—testicular cancer	0.000179	0.00462	CbGpPWpGaD
Dabrafenib—Diarrhoea—Cisplatin—testicular cancer	0.000178	0.000761	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR—KITLG—testicular cancer	0.000177	0.00458	CbGpPWpGaD
Dabrafenib—Alopecia—Methotrexate—testicular cancer	0.000177	0.000759	CcSEcCtD
Dabrafenib—BRAF—Signaling by FGFR in disease—KIT—testicular cancer	0.000176	0.00455	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—KITLG—testicular cancer	0.000176	0.00455	CbGpPWpGaD
Dabrafenib—Mental disorder—Methotrexate—testicular cancer	0.000176	0.000752	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000176	0.00454	CbGpPWpGaD
Dabrafenib—Eye disorder—Epirubicin—testicular cancer	0.000175	0.000751	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—testicular cancer	0.000175	0.00075	CcSEcCtD
Dabrafenib—RAF1—Signaling by PDGF—KITLG—testicular cancer	0.000175	0.00452	CbGpPWpGaD
Dabrafenib—Malnutrition—Methotrexate—testicular cancer	0.000175	0.000747	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—testicular cancer	0.000175	0.000747	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—testicular cancer	0.000174	0.000747	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—testicular cancer	0.000174	0.000743	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—testicular cancer	0.000171	0.000734	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—testicular cancer	0.000171	0.000732	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—testicular cancer	0.000171	0.000731	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—testicular cancer	0.000171	0.000731	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—testicular cancer	0.00017	0.000729	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—testicular cancer	0.00017	0.000729	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00017	0.00439	CbGpPWpGaD
Dabrafenib—Immune system disorder—Epirubicin—testicular cancer	0.000169	0.000726	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—testicular cancer	0.000169	0.000724	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—testicular cancer	0.000169	0.000723	CcSEcCtD
Dabrafenib—Chills—Epirubicin—testicular cancer	0.000168	0.000721	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—testicular cancer	0.000168	0.00072	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—testicular cancer	0.000168	0.000718	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—testicular cancer	0.000166	0.00071	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—testicular cancer	0.000165	0.000707	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—testicular cancer	0.000164	0.000704	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—testicular cancer	0.000164	0.000704	CcSEcCtD
Dabrafenib—Rash—Cisplatin—testicular cancer	0.000164	0.000701	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—testicular cancer	0.000163	0.0007	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—testicular cancer	0.000163	0.000699	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—testicular cancer	0.000163	0.000699	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—testicular cancer	0.000163	0.000697	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—testicular cancer	0.000162	0.000695	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—testicular cancer	0.000161	0.000691	CcSEcCtD
Dabrafenib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000161	0.00415	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000159	0.00412	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000158	0.00409	CbGpPWpGaD
Dabrafenib—Back pain—Epirubicin—testicular cancer	0.000158	0.000677	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—testicular cancer	0.000157	0.000675	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—testicular cancer	0.000157	0.000673	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—testicular cancer	0.000157	0.000672	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—testicular cancer	0.000157	0.000672	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—testicular cancer	0.000156	0.00067	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—testicular cancer	0.000156	0.000669	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000156	0.00403	CbGpPWpGaD
Dabrafenib—Chills—Doxorubicin—testicular cancer	0.000156	0.000667	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—testicular cancer	0.000155	0.000664	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—testicular cancer	0.000154	0.00066	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—testicular cancer	0.000154	0.000659	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—testicular cancer	0.000153	0.000657	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000152	0.00394	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000152	0.00394	CbGpPWpGaD
Dabrafenib—Cough—Methotrexate—testicular cancer	0.000152	0.000652	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—testicular cancer	0.000152	0.000651	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—testicular cancer	0.000151	0.000647	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—testicular cancer	0.000151	0.000647	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—testicular cancer	0.000151	0.000647	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—testicular cancer	0.000151	0.000646	CcSEcCtD
Dabrafenib—RAF1—Signaling by GPCR—INSL3—testicular cancer	0.00015	0.00388	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—FGFR3—testicular cancer	0.00015	0.00388	CbGpPWpGaD
Dabrafenib—Rash—Etoposide—testicular cancer	0.00015	0.000642	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—testicular cancer	0.00015	0.000642	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—FGFR3—testicular cancer	0.000149	0.00386	CbGpPWpGaD
Dabrafenib—Headache—Etoposide—testicular cancer	0.000149	0.000638	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—testicular cancer	0.000149	0.000636	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—testicular cancer	0.000149	0.000636	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000148	0.000632	CcSEcCtD
Dabrafenib—CYP2C8—Biological oxidations—HPGDS—testicular cancer	0.000147	0.0038	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000146	0.00378	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—KIT—testicular cancer	0.000146	0.00378	CbGpPWpGaD
Dabrafenib—Leukopenia—Epirubicin—testicular cancer	0.000146	0.000626	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—testicular cancer	0.000146	0.000626	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—testicular cancer	0.000145	0.000622	CcSEcCtD
Dabrafenib—RAF1—Downstream signal transduction—FGFR3—testicular cancer	0.000143	0.0037	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—FGFR3—testicular cancer	0.000143	0.00368	CbGpPWpGaD
Dabrafenib—Cough—Epirubicin—testicular cancer	0.000143	0.00061	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—testicular cancer	0.000142	0.00061	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB2—FGFR3—testicular cancer	0.000142	0.00367	CbGpPWpGaD
Dabrafenib—Infection—Methotrexate—testicular cancer	0.000141	0.000606	CcSEcCtD
Dabrafenib—Nausea—Etoposide—testicular cancer	0.000141	0.000605	CcSEcCtD
Dabrafenib—RAF1—DAP12 signaling—FGFR3—testicular cancer	0.000141	0.00365	CbGpPWpGaD
Dabrafenib—Hypertension—Epirubicin—testicular cancer	0.000141	0.000604	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.00014	0.00362	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Methotrexate—testicular cancer	0.00014	0.000598	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—testicular cancer	0.00014	0.000598	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—testicular cancer	0.000139	0.000597	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—testicular cancer	0.000139	0.000595	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—testicular cancer	0.000139	0.000595	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—testicular cancer	0.000138	0.000592	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000138	0.000591	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—KIT—testicular cancer	0.000138	0.00356	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Methotrexate—testicular cancer	0.000138	0.00059	CcSEcCtD
Dabrafenib—LIMK1—Developmental Biology—MMP2—testicular cancer	0.000137	0.00355	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—KIT—testicular cancer	0.000137	0.00354	CbGpPWpGaD
Dabrafenib—Dry mouth—Epirubicin—testicular cancer	0.000136	0.000582	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—testicular cancer	0.000135	0.000579	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—testicular cancer	0.000133	0.000571	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—testicular cancer	0.000133	0.00057	CcSEcCtD
Dabrafenib—RAF1—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000133	0.00343	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—FGFR3—testicular cancer	0.000133	0.00343	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000133	0.00343	CbGpPWpGaD
Dabrafenib—Infection—Epirubicin—testicular cancer	0.000132	0.000567	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—testicular cancer	0.000132	0.000565	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR—FGFR3—testicular cancer	0.000132	0.0034	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—KIT—testicular cancer	0.000132	0.0034	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—KIT—testicular cancer	0.000131	0.00338	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—FGFR3—testicular cancer	0.000131	0.00338	CbGpPWpGaD
Dabrafenib—Nervous system disorder—Epirubicin—testicular cancer	0.000131	0.00056	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000131	0.00337	CbGpPWpGaD
Dabrafenib—Thrombocytopenia—Epirubicin—testicular cancer	0.000131	0.000559	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—testicular cancer	0.00013	0.000559	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB2—KIT—testicular cancer	0.00013	0.00337	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—FGFR3—testicular cancer	0.00013	0.00336	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00013	0.000556	CcSEcCtD
Dabrafenib—RAF1—DAP12 signaling—KIT—testicular cancer	0.00013	0.00335	CbGpPWpGaD
Dabrafenib—Skin disorder—Epirubicin—testicular cancer	0.000129	0.000554	CcSEcCtD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000129	0.00333	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Epirubicin—testicular cancer	0.000129	0.000552	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—testicular cancer	0.000129	0.000552	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—testicular cancer	0.000129	0.000551	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—testicular cancer	0.000129	0.000551	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways—INSL3—testicular cancer	0.000128	0.00332	CbGpPWpGaD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000128	0.000547	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—testicular cancer	0.000126	0.000539	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—testicular cancer	0.000125	0.000533	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—testicular cancer	0.000124	0.00053	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—testicular cancer	0.000123	0.000528	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000123	0.000527	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—testicular cancer	0.000123	0.000526	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—testicular cancer	0.000123	0.000525	CcSEcCtD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000122	0.00315	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—KIT—testicular cancer	0.000122	0.00315	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—KIT—testicular cancer	0.000122	0.00315	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—KITLG—testicular cancer	0.000122	0.00315	CbGpPWpGaD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000121	0.00052	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—testicular cancer	0.000121	0.000518	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR—KIT—testicular cancer	0.000121	0.00312	CbGpPWpGaD
Dabrafenib—Thrombocytopenia—Doxorubicin—testicular cancer	0.000121	0.000517	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—testicular cancer	0.000121	0.000516	CcSEcCtD
Dabrafenib—BRAF—Signaling by NGF—KIT—testicular cancer	0.00012	0.0031	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00012	0.0031	CbGpPWpGaD
Dabrafenib—Skin disorder—Doxorubicin—testicular cancer	0.00012	0.000513	CcSEcCtD
Dabrafenib—RAF1—Signaling by PDGF—KIT—testicular cancer	0.000119	0.00308	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Doxorubicin—testicular cancer	0.000119	0.000511	CcSEcCtD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000118	0.00305	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000118	0.00304	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—KITLG—testicular cancer	0.000117	0.00302	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Methotrexate—testicular cancer	0.000116	0.000499	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—testicular cancer	0.000116	0.000496	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—testicular cancer	0.000115	0.000494	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—BCL10—testicular cancer	0.000115	0.00298	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000115	0.000493	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—testicular cancer	0.000115	0.000492	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—testicular cancer	0.000114	0.000488	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—testicular cancer	0.000113	0.000482	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—testicular cancer	0.000113	0.000482	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000112	0.000481	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—testicular cancer	0.000112	0.000478	CcSEcCtD
Dabrafenib—RAF1—Adaptive Immune System—BCL10—testicular cancer	0.000111	0.00286	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Epirubicin—testicular cancer	0.000109	0.000467	CcSEcCtD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000108	0.00279	CbGpPWpGaD
Dabrafenib—Decreased appetite—Doxorubicin—testicular cancer	0.000107	0.000459	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000106	0.000456	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—testicular cancer	0.000106	0.000455	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—testicular cancer	0.000105	0.000452	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—testicular cancer	0.000105	0.000451	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—testicular cancer	0.000105	0.000451	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—testicular cancer	0.000105	0.000449	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—testicular cancer	0.000102	0.000438	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000101	0.000432	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—testicular cancer	0.000101	0.000432	CcSEcCtD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.84e-05	0.00254	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Epirubicin—testicular cancer	9.82e-05	0.000421	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—testicular cancer	9.75e-05	0.000418	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—testicular cancer	9.75e-05	0.000418	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—testicular cancer	9.74e-05	0.000417	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—testicular cancer	9.56e-05	0.00041	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—testicular cancer	9.43e-05	0.000404	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—testicular cancer	9.42e-05	0.000403	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—testicular cancer	9.12e-05	0.000391	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—testicular cancer	9.09e-05	0.000389	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—testicular cancer	9.06e-05	0.000388	CcSEcCtD
Dabrafenib—RAF1—Signaling by NGF—FGFR3—testicular cancer	9.05e-05	0.00234	CbGpPWpGaD
Dabrafenib—Rash—Methotrexate—testicular cancer	8.98e-05	0.000385	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—testicular cancer	8.97e-05	0.000384	CcSEcCtD
Dabrafenib—Headache—Methotrexate—testicular cancer	8.92e-05	0.000382	CcSEcCtD
Dabrafenib—RAF1—Signaling Pathways—INSL3—testicular cancer	8.88e-05	0.00229	CbGpPWpGaD
Dabrafenib—Asthenia—Doxorubicin—testicular cancer	8.85e-05	0.000379	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—testicular cancer	8.81e-05	0.000377	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—testicular cancer	8.73e-05	0.000374	CcSEcCtD
Dabrafenib—LIMK1—Immune System—FGFR3—testicular cancer	8.69e-05	0.00225	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	8.57e-05	0.00221	CbGpPWpGaD
Dabrafenib—Vomiting—Epirubicin—testicular cancer	8.47e-05	0.000363	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—testicular cancer	8.46e-05	0.000362	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—testicular cancer	8.44e-05	0.000361	CcSEcCtD
Dabrafenib—Rash—Epirubicin—testicular cancer	8.4e-05	0.00036	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—testicular cancer	8.4e-05	0.00036	CcSEcCtD
Dabrafenib—Headache—Epirubicin—testicular cancer	8.35e-05	0.000358	CcSEcCtD
Dabrafenib—RAF1—Signaling by NGF—KIT—testicular cancer	8.31e-05	0.00215	CbGpPWpGaD
Dabrafenib—Dizziness—Doxorubicin—testicular cancer	8.16e-05	0.000349	CcSEcCtD
Dabrafenib—LIMK1—Immune System—KIT—testicular cancer	7.98e-05	0.00206	CbGpPWpGaD
Dabrafenib—Nausea—Epirubicin—testicular cancer	7.92e-05	0.000339	CcSEcCtD
Dabrafenib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	7.91e-05	0.00204	CbGpPWpGaD
Dabrafenib—Vomiting—Doxorubicin—testicular cancer	7.84e-05	0.000336	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—testicular cancer	7.78e-05	0.000333	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—testicular cancer	7.77e-05	0.000333	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—testicular cancer	7.73e-05	0.000331	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—testicular cancer	7.33e-05	0.000314	CcSEcCtD
Dabrafenib—RAF1—Innate Immune System—KITLG—testicular cancer	6.95e-05	0.00179	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL10—testicular cancer	6.71e-05	0.00173	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KITLG—testicular cancer	6.67e-05	0.00172	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP2—testicular cancer	6.66e-05	0.00172	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—HPGDS—testicular cancer	6.52e-05	0.00169	CbGpPWpGaD
Dabrafenib—BRAF—Disease—H2AFZ—testicular cancer	5.87e-05	0.00152	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.66e-05	0.00146	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KITLG—testicular cancer	5.4e-05	0.00139	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FGFR3—testicular cancer	5.16e-05	0.00133	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—FGFR3—testicular cancer	4.96e-05	0.00128	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP2—testicular cancer	4.76e-05	0.00123	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—STK11—testicular cancer	4.74e-05	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—KIT—testicular cancer	4.74e-05	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—KIT—testicular cancer	4.55e-05	0.00118	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HPGDS—testicular cancer	4.38e-05	0.00113	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—H2AFZ—testicular cancer	4.11e-05	0.00106	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STK11—testicular cancer	4.09e-05	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Disease—H2AFZ—testicular cancer	4.06e-05	0.00105	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HPGDS—testicular cancer	4.06e-05	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KITLG—testicular cancer	4.05e-05	0.00105	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGFR3—testicular cancer	4.01e-05	0.00104	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KITLG—testicular cancer	3.78e-05	0.000977	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KITLG—testicular cancer	3.74e-05	0.000965	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KIT—testicular cancer	3.68e-05	0.000952	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—STK11—testicular cancer	3.18e-05	0.000823	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGFR3—testicular cancer	3.01e-05	0.000777	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—STK11—testicular cancer	2.95e-05	0.000762	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—H2AFZ—testicular cancer	2.84e-05	0.000734	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STK11—testicular cancer	2.83e-05	0.00073	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGFR3—testicular cancer	2.81e-05	0.000726	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGFR3—testicular cancer	2.78e-05	0.000717	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KIT—testicular cancer	2.76e-05	0.000713	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KITLG—testicular cancer	2.62e-05	0.000676	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KIT—testicular cancer	2.58e-05	0.000666	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KIT—testicular cancer	2.55e-05	0.000658	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HPGDS—testicular cancer	2.52e-05	0.000651	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HPGDS—testicular cancer	2.19e-05	0.000567	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR3—testicular cancer	1.94e-05	0.000502	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STK11—testicular cancer	1.83e-05	0.000473	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—testicular cancer	1.78e-05	0.000461	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STK11—testicular cancer	1.59e-05	0.000412	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—testicular cancer	1.35e-05	0.000349	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STK11—testicular cancer	9.82e-06	0.000254	CbGpPWpGaD
